Navigation Links
Duska Therapeutics Sponsored University of Pennsylvania Study Demonstrates ATP Improves Sperm Motility and In Vitro Fertilization in Animals
Date:5/14/2008

LA JOLLA, Calif., May 14 /PRNewswire-FirstCall/ -- Duska Therapeutics, Inc. (OTC Bulletin Board: DSKA.OB) ("Duska" or the "Company") announced today that scientists from the University of Pennsylvania's Center for Research on Reproduction and Women's Health have published the results of the Company's sponsored study showing that extracellular ATP (adenosine 5'-triphosphate) improves sperm motility and increases fertilizing capability in mice.

The data was published online in the journal Biology of Reproduction (http://www.biolreprod.org/cgi/content/abstract/biolreprod.107.065565).

The University of Pennsylvania scientists studied sperm obtained from two mouse strains: one with normal and the other one with low fertilization capacity. Extracellular ATP treatment of these sperm in vitro (outside of the body) resulted in improved sperm motility parameters and was associated with a rapid increase in the level of intracellular calcium. The effect was inhibited by two P2 receptor antagonists. Furthermore, extracellular ATP treatment of mouse sperm resulted in increased success rates of in vitro fertilization (IVF) procedures. The improved fertilization rate was much more pronounced when sperm from the mouse strain with low fertility were used.

The authors suggest that ATP's activation of P2 receptors to modulate sperm function may be beneficial for artificial reproductive techniques.

"We are extremely pleased with the positive results of sperm treatment with ATP, which were obtained in this second Duska-sponsored study," said Dr. Amir Pelleg, Duska's President and Chief Scientific Officer. "These results indicate that the mechanism of action of extracellular ATP on improving sperm motility and fertilization potency is mediated by P2 receptors and increased level of intracellular calcium. The data further support the development of ATPotent(TM), which contains ATP, as a novel processing medium to improve sperm motility when used in conjunction with IVF or IUI procedures," he added.

No human embryos were created or destroyed in this Duska-sponsored study

About Male Infertility and ATPotent(TM)

Asthenozoospermia, i.e., lack of or low sperm motility, is a common cause of human male infertility. It has been reported in the medical literature that the prevalence of altered sperm motility in infertile men is approximately 82%. Currently, there is no FDA-approved product that improves sperm motility. Duska's proprietary ATPotent(TM) is being developed as a novel processing medium to improve sperm motility in conjunction with IVF or IUI procedures. One component of ATPotent(TM) is ATP, a naturally occurring biological molecule that is found in all human cells. Naturally occurring ATP in the female reproductive tract is believed to play a facilitating role in normal egg fertilization. Several in vitro studies conducted on sperm of human and several animal species suggest that extracellular ATP treatment of poorly motile sperm improves motility parameters and increases the success rate of IVF procedures.

About Duska Therapeutics, Inc.

Duska Therapeutics, Inc., based in La Jolla, California, is a biotechnology company focused on the development of medical products based on ATP (adenosine 5'-triphosphate). Duska owns or has exclusive licensing rights to proprietary medical products that are in various stages of development for the treatment and diagnosis of certain cardiac arrhythmias, improvement of sperm motility, treatment of chronic obstructive pulmonary disorder and chronic cough, and mitigation of the toxic effects of radiation exposure. For more information on the company, visit Duska's website at http://www.duskatherapeutics.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements. The forward-looking statements are based on current expectations, estimates and projections made by management. Duska intends for the forward-looking statements to be covered by the safe harbor provisions for forward-looking statements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," or variations of such words are intended to identify such forward-looking statements. All statements in this release regarding the future outlook related to Duska are forward-looking statements, including the statements that these results indicate that the mechanism of action of extracellular ATP on improving sperm motility and fertilization potency is mediated by P2 receptors and increased level of intracellular calcium and that the data further support the development of ATPotent(TM), which contains ATP, as a novel processing medium to enhance sperm motility when used in conjunction with IVF or IUI procedures. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Additional uncertainties and risks are described in Duska's most recently filed SEC documents, such as its most recent annual report on Form 10-KSB, all quarterly reports on Form 10-QSB and any current reports on Form 8-K filed since the date of the last Form 10-KSB. Copies of these filings are available through the SEC website at http://www.sec.gov. All forward-looking statements are based upon information available to Duska on the date hereof. Duska undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by law.


'/>"/>
SOURCE Duska Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Duska Therapeutics Plans 505(b)(2) NDA Filing Route for ATPace(TM)
2. Transition Therapeutics to Hold Conference Call on Third Quarter Fiscal 2008 Financial Results on Wednesday, May 14, 2008 at 4:30 P.M. EST
3. TorreyPines Therapeutics Reports First Quarter 2008 Financial Results and Accomplishments
4. Jane Moffitt, J.D., LL.M. Named Vice President of Regulatory Affairs of Nile Therapeutics
5. Zevalin Revenues Lead Cell Therapeutics, Inc.s First Quarter 2008 Financial Results
6. Nektar Therapeutics Announces First Quarter 2008 Results
7. TorreyPines Therapeutics Licenses Intellectual Property from Johns Hopkins Related to Novel Uses of Glutamate Receptor Antagonists for Prevention, Treatment of Stroke, Heart Attack
8. Transition Therapeutics to Present at 2008 Morgan Stanley Global Healthcare Unplugged Conference
9. Echo Therapeutics and Cato BioVentures Sign Right of First Offer Agreement for Dermatology Products and Transdermal Drug Delivery Technologies
10. CV Therapeutics to Announce 2008 First Quarter Financial Results on Friday, April 25, 2008
11. Precision Therapeutics Adds 8 Million Covered Lives Under Contract
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... Houston, TX (PRWEB) , ... July 24, 2017 , ... ... $1000 student scholarship will be awarded for the fall semester to a deserving student. ... SignatureCare Emergency Centers Spring 2017 scholarship was awarded to Mariana Castillo who is a ...
(Date:7/24/2017)... ... July 24, 2017 , ... Horizon Goodwill Industries, ... unique opportunity that helps high school girls succeed in STEM programs as well ... Horizon Goodwill will host over 20 high school girls at their corporate headquarters ...
(Date:7/24/2017)... ... July 24, 2017 , ... The International Essential Tremor Foundation (IETF) will host ... tremor (ET). The seminar will take place on Saturday, Aug. 26 at the Embassy ... program will run from 9 a.m. to 12 p.m., with check-in beginning at 8 ...
(Date:7/24/2017)... NY (PRWEB) , ... July 24, 2017 , ... ... series of media initiatives designed to promote awareness for Topricin’s revolutionary, natural, after-burn ... elements is one of the leading causes of long term skin conditions, including ...
(Date:7/24/2017)... ... July 24, 2017 , ... Puregraft, the global leader in ... of United States Patent Number 9,695,398 (the '398 patent) and South Korean Patent ... and '324 patents cover methods and systems for optimizing fat grafts for current ...
Breaking Medicine News(10 mins):
(Date:7/14/2017)... It should come as no surprise to anyone ... the midst of a crippling opioid epidemic. According to the ... of overdose deaths from opiate-based medications has quadrupled, Says, Dr. ... dead from 2001 to 2015". During this time, the prescription ... quadrupled, drawing a compelling link between prescription and eventual addiction. ...
(Date:7/13/2017)... ROCKVILLE, Md. , July 13, 2017  New York ... watchers of pharmaceutical markets should be aware of.  From new ... These trends are detailed in a recently completed study, ... following: 1.  Age-Driven ... years, we have been aware of the impact the growing ...
(Date:7/11/2017)... 11, 2017 Zymo Research Corp., also known as ,The Epigenetics ... biological aging in a precise manner using the myDNAge ™ test. ... a professor of human genetics and biostatistics at the David Geffen ... Health , Zymo Research,s proprietary DNAge ™ technology is used to ... ...
Breaking Medicine Technology: